New York, NY -- (SBWIRE) -- 01/21/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Hersha Hospitality Trust (NYSE:HT), AVEO Pharmaceuticals, Inc (NASDAQ:AVEO), American Lorain Corporation (NYSEMKT:ALN), CytRx Corporation (NASDAQ:CYTR)
Hersha Hospitality Trust (NYSE:HT) showed a volume of 1.49 million shares by the end of last trade whereas the average volume of the stock remained 1.59 million shares. The stock opened the session at $5.55 but then moved to $5.60. At that price, the stock showed a positive performance of 0.54%. Hersha Hospitality Trust is a self-advised Maryland real estate investment trust. The Company invests primarily in institutional grade hotels in urban and central business districts, primary suburban office markets and stable destination and secondary markets in the Northeastern United States,
Will HT Continue To Move Higher? Find Out Here
AVEO Pharmaceuticals, Inc (NASDAQ:AVEO) opened the session at $2.03 and closed the session at $2.00. The stock showed a negative performance of -0.50% in previous trading session. Traded with volume of 1.48 million shares in the prior session and the average volume of the stock remained 817,443.00 shares. AVEO Pharmaceuticals, Inc. is a cancer therapeutics company discovering, developing and commercializing targeted cancer therapies. The Company’s Human Response Platform,
Has AVEO Found The Bottom And Ready To Gain Momentum? Find Out Here
American Lorain Corporation (NYSEMKT:ALN) opened the session at $0.88 and closed the session at $0.970. The stock showed a positive performance of 8.99% in previous trading session. Traded with volume of 1.48million shares in the prior session and the average volume of the stock remained 269,907.00 shares. The beta of the stock remained 1.66. American Lorain Corporation (ALN) is an integrated food manufacturing company. The Company develops, manufactures and sells food products, which includes chestnut products,
Why Should Investors Buy ALN After The Recent Gain? Just Go Here and Find Out
CytRx Corporation (NASDAQ:CYTR) the stock advanced 1.00% and finished the session at $7.04. Traded with volume of 1.47million shares in the prior session and the average volume of the stock remained 6.21 million shares. The beta of the stock remained 1.33. CytRx Corporation (CytRx) is a biopharmaceutical research and development company specializing in oncology. The Company's oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib.
Will CYTR Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)